BAVENCIO®
avelumab Injection

LONGER OVERALL SURVIVAL

IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA[1]

NOW APPROVED

+7.1 MONTHS
prolonged overall survival[1]

INCLUDED IN GUIDELINES
ESMO, EAU, NCCN[2-4]

BROAD USE
independent on PD-L1 expression[5]

BAVENCIO® as first-line switch maintenance therapy after platinum-containing chemotherapy can preserve the benefits achieved with chemotherapy and significantly prolong patients' lives.[1]

MERCK Pfizer

Longer overall survival in locally advanced or metastatic urothelial carcinoma[1]

BAVENCIO® + BSC demonstrated superior mOS vs BSC alone among **all randomized patients**[1]



31%
reduction in the risk of death
HR: 0.69
(95% CI: 0.56, 0.86)
2-sided P=0.001

7.1 MONTH
improvement in mOS

No new safety signals identified[1]

In the overall population, any cause adverse events occurred in 98 % of BAVENCIO® + BSC treated patients, versus 77.7 % of patients in the control group. The most common adverse events of grade 3 or higher in the BAVENCIO® + BSC arm were urinary tract infections, anemia, fatigue, and hematuria.[1]
Quality of life was not negatively impacted during administration of BAVENCIO®.[6]

Premedication[5]

Prior to the first 4 infusions of BAVENCIO® premedication is necessary with
- **antihistamine**
- **paracetamol**

Dosage[5]

The recommended dose of BAVENCIO® is **10 mg/kg body weight every 2 weeks**.

Administration[5]

BAVENCIO® is administered **intravenously over 60 minutes**.

BSC=best supportive care, CI=confidence interval, HR=hazard ratio, mOS=median overall survival

References
1. Powles T, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218-1230. doi:10.1056/NEJMoa2002788 **2.** ESMO Guidelines Committee. eUpdate—Bladder cancer treatment recommendations. July 16, 2020. https://www.esmo.org/guidelines/genitourinary-cancers/ bladder-cancer/eupdate-bladder-cancer-treatment-recommendations4. Accessed July 2021. **3.** EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4. **4.** National Comprehensive Cancer Network® (NCCN Guidelines®). Bladder Cancer (version 2.2021). https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed July 2021. **5.** Current BAVENCIO® (Avelumab) product information, www.swissmedicfinfo.ch. **6.** Powles T, et al. Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance+BSC vs BSC alone for advanced urothelial carcinoma. Poster presented at ESMO Virtual Congress 2020,14. Sep-18. Oct, Abstract No. 2653.

Bavencio® (20 mg/ml avelumab, fully human immunoglobulin G1 monoclonal antibody).
I: For the treatment of patients with metastatic Merkel cell carcinoma (MCC). As monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy. **PO:** 10 mg/kg body weight once every 2 weeks, administered intravenously over 60 minutes until disease progression or unacceptable toxicity. Premedication with an antihistamine and with paracetamol at least prior to the first 4 infusions. Handling instructions and guidelines for withholding or discontinuation of the therapy are to be strictly adhered to. **CI:** Hypersensitivity to avelumab or to any of the excipients. **W:** Immune-related adverse reactions including haemophagocytic lymphohistiocytosis, immune-related pneumonitis, immune-related hepatitis, immune-related colitis, immune-related pancreatitis, immune-related myocarditis, immune-related endocrinopathies (hypothyroidism or hyperthyroidism, adrenal insufficiency, type 1 diabetes mellitus), immune-related nephritis. Infusion-related reactions which might be severe. Adverse events in transplant recipients, embryofoetal toxicity. **IA:** None known. **Most common UE:** Immune-related adverse reactions and infusion-related reactions. Headache, dizziness, neuropathy peripheral, hypertension, hypotension, dry mouth, increased liver values, fatigue, pyrexia, asthenia, chills, influenza like illness, nausea, vomiting, diarrhoea, constipation, decreased appetite, weight decreased, hyponatraemia, abdominal pain, urinary tract infection, dyspnoea, cough, pneumonitis, dysphonia, rash, pruritus, dry skin, anaemia, lymphopenia, thrombocytopenia, hypothyroidism, hyperthyroidism, back pain, arthralgia, myalgia, creatinine, amylase or lipase increased, peripheral oedema. **P:** 1 + 4 vials of 10 ml (200 mg avelumab). [A] For further information, see www.swissmedicinfo.ch. AUG21

Marketing Authorisation Holder: Merck (Schweiz) AG, Chamerstrasse 174, CH-6300 Zug, info@merck.ch, www.merck.ch

CH-AVEBL-00049